Valence ロゴ
人気
ログイン
Loading data for NONOF — first visit, this takes a few seconds.

ウォッチリストに追加

Novo Nordisk A/S

OTC Markets OTCPK: NONOF · リアルタイム株価 · USD
45.02
-1.14 (-2.47%)
終値時点： Aug 28, 2026, 11:52 AM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Novo Nordisk A/S（NONOF）の株価・分析・データ

-2.47%
買気配44.59
時価総額199.03B
売上高（TTM）329.43B
純利益（TTM）116.44B
0.35
4.2
10.72
n/a
PBR（TTM）5.77
PSR（TTM）0.60
決算発表日Nov 4, 2026
売気配45.67
出来高265
平均出来高（20日）65,274
始値45.52
前日終値46.16
当日レンジ45.52 - 45.52
52週レンジ34.00 - 64.75
アナリストn/a
目標株価n/a
配当$1.8 (4%)
権利落ち日2026年8月14日

NONOFについて

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine...

[続きを読む]
業種 Drug Manufacturers - General
セクター Healthcare
IPO日 Feb 22, 2010
従業員数 66,700
上場取引所 OTC Markets OTCPK
ティッカー NONOF
ウェブサイト https://www.novonordisk.com
企業情報の全文

業績

2025年のNovo Nordisk A/Sの売上高は309.06Bで、前年の290.4Bから6.43%の増加でした。 利益は102.43Bで、1.43%の増加でした。

財務諸表

次回決算発表

Novo Nordisk A/Sの決算発表予定日は Nov 4, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード
news image

8時間前 · Motley Fool

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

news image

12時間前 · Motley Fool

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

news image

1日前 · Motley Fool

Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

news image

2日前 · GuruFocus.com

Novo's Wegovy Pill Enters China Behind Lilly

Regulatory acceptance opens the door, but it neither guarantees approval nor repairs Novo's late start.

news image

2日前 · USA TODAY

Eli Lilly's diabetes drug Mounjaro gets approval for a new use

The FDA approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes.

2ページ中1ページ